Blocklisting Six Monthly Return

RNS Number : 2982R

Hutchison China Meditech Limited

29 June 2020

 

Blocklisting Six Monthly Return

London: Monday, June 29, 2020 : Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

1.	Name of applicant:		Hutchison China MediTech Limited
2.	Name of scheme:		(a)	Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 ("2005 HCML Share Option Scheme")
			(b)	Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 ("2015 HCML Share Option Scheme")
3.	Period of return:		From December 29, 2019 to June 28, 2020
4.	Balance under scheme from previous return:		(a)	2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each
			(b)	2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each
5.	The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		(a)	2005 HCML Share Option Scheme: Nil
			(b)	2015 HCML Share Option Scheme: Nil
6.	Number of securities issued/allotted under scheme during period:		(a)	2005 HCML Share Option Scheme: Nil
			(b)	2015 HCML Share Option Scheme: Nil
7.	Balance under scheme not yet issued/allotted at end of the period:		(a)	2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each
			(b)	2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each
8.	Number and class of securities originally listed and the date of admission:		25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 ( to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019)
9.	Total number of securities in issue at the end of the period:		690,574,765 ordinary shares of US$0.1 each
Name of contact:			Christian Hogg
Address of contact:			Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
Telephone number of contact:			[phone]

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	[phone]
Annie Cheng, Vice President	[phone]
Media Enquiries
Americas - Brad Miles, Solebury Trout	[phone]   (Mobile)  [e-mail]
Europe - Ben Atwell / Alex Shaw, FTI Consulting	[phone] / [phone]   (Mobile) / [phone] (Mobile) [e-mail]
Asia - Joseph Chi Lo / Zhou Yi, Brunswick	[phone] (Mobile), [e-mail] / [phone] (Mobile), y [e-mail]
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited	[phone]

 

END

 

 

BLRUWOARRKUNUUR